Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie H, Weiss B, Chowers Y.

Clin Gastroenterol Hepatol. 2013 Apr;11(4):444-7. doi: 10.1016/j.cgh.2012.10.020. Epub 2012 Oct 24.

PMID:
23103905
2.

Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.

Abraham NS, Richardson P, Castillo D, Kane SV.

Clin Gastroenterol Hepatol. 2013 Oct;11(10):1281-7. doi: 10.1016/j.cgh.2013.06.004. Epub 2013 Jun 19.

PMID:
23792295
3.

Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.

Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):514-521.e4. doi: 10.1016/j.cgh.2014.07.027. Epub 2014 Jul 25.

PMID:
25066841
4.

Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):522-530.e2. doi: 10.1016/j.cgh.2014.07.029. Epub 2014 Jul 25.

PMID:
25066837
5.

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.

Pallagi-Kunstár É, Farkas K, Szepes Z, Nagy F, Szűcs M, Kui R, Gyulai R, Bálint A, Wittmann T, Molnár T.

World J Gastroenterol. 2014 May 7;20(17):5031-5. doi: 10.3748/wjg.v20.i17.5031.

6.

Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.

Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D, Colombel JF, Allez M.

Inflamm Bowel Dis. 2012 Jul;18(7):1199-206. doi: 10.1002/ibd.21839. Epub 2011 Aug 29.

PMID:
22127789
7.

Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.

Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, Lockton S, Rutgeerts P, Vermeire S.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1474-81.e2; quiz e91. doi: 10.1016/j.cgh.2014.01.033. Epub 2014 Jan 29.

PMID:
24486408
8.

Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.

Lee LY, Sanderson JD, Irving PM.

Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1078-85. doi: 10.1097/MEG.0b013e32835558cf.

PMID:
22647738
9.

Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD.

van Schaik T, Maljaars JP, Roopram RK, Verwey MH, Ipenburg N, Hardwick JC, Veenendaal RA, van der Meulen-de Jong AE.

Inflamm Bowel Dis. 2014 Dec;20(12):2292-8. doi: 10.1097/MIB.0000000000000208.

PMID:
25230167
10.

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease.

Imaeda H, Andoh A, Fujiyama Y.

J Gastroenterol. 2012 Feb;47(2):136-43. doi: 10.1007/s00535-011-0474-y. Epub 2011 Sep 28.

PMID:
21953314
11.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P.

Gut. 2007 Sep;56(9):1226-31. Epub 2007 Jan 17.

12.

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.

Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E, Coscas D, Bar-Meir S, Goldstein I, Chowers Y.

Gut. 2011 Jan;60(1):41-8. doi: 10.1136/gut.2009.201533. Epub 2010 Jun 2.

PMID:
20519742
13.

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM.

Clin Ther. 2011 Jul;33(7):946-64. doi: 10.1016/j.clinthera.2011.06.002. Epub 2011 Jul 7.

PMID:
21741088
14.

Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.

Ungar B, Haj-Natour O, Kopylov U, Yavzori M, Fudim E, Picard O, Loebstein R, Lahat A, Maor Y, Avidan B, Lang A, Weiss B, Chowers Y, Eliakim R, Ben-Horin S.

Medicine (Baltimore). 2015 May;94(18):e673. doi: 10.1097/MD.0000000000000673.

15.

Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies.

Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D, Picard O, Chowers Y, Eliakim R, Ben-Horin S.

Inflamm Bowel Dis. 2012 Sep;18(9):1628-33. doi: 10.1002/ibd.21919. Epub 2011 Oct 29.

PMID:
22038899
16.

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD.

Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M, Picard O, Fudim E, Maor Y, Lahat A, Coscas D, Eliakim R, Dotan I, Chowers Y.

Aliment Pharmacol Ther. 2012 Mar;35(6):714-22. doi: 10.1111/j.1365-2036.2012.04997.x. Epub 2012 Jan 30.

17.

Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.

Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ, van der Woude CJ; Dutch Delta IBD Group.

Clin Gastroenterol Hepatol. 2013 Mar;11(3):318-21. doi: 10.1016/j.cgh.2012.10.024. Epub 2012 Oct 25.

PMID:
23103819
18.

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.

Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ.

Am J Gastroenterol. 2010 May;105(5):1133-9. doi: 10.1038/ajg.2010.9. Epub 2010 Feb 9.

PMID:
20145610
19.

Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab.

Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS.

Dig Dis Sci. 2010 May;55(5):1413-20. doi: 10.1007/s10620-009-0856-7. Epub 2009 Jun 18.

PMID:
19533357
20.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984

Supplemental Content

Support Center